[{"orgOrder":0,"company":"Adtech Pharma","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nabilone","moa":"CB1","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Adtech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Adtech Pharma \/ Ault Global Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Adtech Pharma \/ Ault Global Holdings"}]

Find Clinical Drug Pipeline Developments & Deals for Cesamet

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : NB-110 comprises of a synthetic cannabinoid Nabilone in the absence of any preservative and its formulation mimics a human tear to drive efficacious delivery through the cornea to the retina and optical nerves in the back of eye.

                          Brand Name : NB-110

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 28, 2021

                          Lead Product(s) : Nabilone

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Ault Global Holdings

                          Deal Size : $3.0 million

                          Deal Type : Acquisition

                          blank